Phase II study of PHA-739358 administered by a 24-hour IV infusion every 14 days in advanced/metastatic breast, ovarian, colorectal, pancreatic, small cell lung and non small cell lung cancers.
收藏NIAID Data Ecosystem2026-03-06 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2520270
下载链接
链接失效反馈官方服务：
资源简介：
Primary objectives: To determine if PHA-739358 has an antitumor activity against breast, ovarian, pancreatic, colorectal, small and non-small cell lung cancers.
Primary endpoints: Progression Free Rate at 4 months of treatment.
创建时间：
2007-09-15
